Genfit S.A. (GNFTY)

Market Cap	228.12M
Revenue (ttm)	52.99M
Net Income (ttm)	-45.52M
Shares Out	n/a
EPS (ttm)	-0.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,316
Average Volume	17,788
Open	4.420
Previous Close	4.445
Day's Range	4.420 - 4.500
52-Week Range	2.550 - 4.929
Beta	n/a
RSI	55.19
Earnings Date	Dec 23, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 180
• Stock Exchange: OTCMKTS
• Ticker Symbol: GNFTY

Financial Performance

Financial numbers in EUR